AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center
New Ampligen-Related Strategy for Treating Advanced Breast Cancer Helps Earn 'Breakthrough Award' OCALA, FL / ACCESSWIRE / September 24, 2019...